Seeking Alpha - 1 天前查看原文
Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025
Alnylam's TTR franchise, powered by Amvuttra, poised for $7.5B peak revenue with undervalued shares and long-term growth potential for investors. See more here.